Details of the Drug

General Information of Drug (ID: DMY6V5T)

Drug Name
ICasp9M28z T cell
Indication
Disease Entry ICD 11 Status REF
Lung cancer 2C25.0 Phase 1 [1]
Malignant pleural effusion 2D72 Phase 1 [1]
Mesothelioma 2C51.2 Phase 1 [1]
Metastatic malignant neoplasm 2D50-2E09 Phase 1 [1]
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D0S9FI
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mesothelin (MSLN) TT4RXME MSLN_HUMAN CAR-T-Cell-Therapy [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Lung cancer
ICD Disease Classification 2C25.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mesothelin (MSLN) DTT MSLN 2.86E-20 3.98 6.12
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02414269) Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin